Impact of comorbidity on complication rates and life expectancy in patients with a leadless pacemaker.
Tardu ÖzkartalAlessia D'AltoMarco BergontiMaria Luce CaputoGiulio ConteAlexander BreitensteinChristian SticherlingAndreas HaeberlinJolie BrunoPeter AmmannChristian GrebmerLuca SchöniElia RigamontiCatherine KlersyAngelo AuricchioPublished in: International journal of cardiology (2024)
In this Swiss, multi-centre, retrospective cohort analysis, 863 patients implanted with a leadless pacemaker were included and divided into a high-comorbidity (with a CCI > 5) and low-comorbidity (with a CCI ≤ 5) group. There was no between group difference in terms of implantation outcomes and peri-operative or long-term complications. Furthermore, all-cause mortality during follow-up in patients with a CCI ≤ 3 was comparable to age- and sex-adjusted mortality in the general Swiss population. These data indicate that LPM implantation is a safe procedure, even in elderly patients with high comorbidity.
Keyphrases
- neuropathic pain
- end stage renal disease
- newly diagnosed
- ejection fraction
- risk factors
- spinal cord
- spinal cord injury
- prognostic factors
- vena cava
- cardiovascular events
- peritoneal dialysis
- cardiovascular disease
- coronary artery disease
- metabolic syndrome
- middle aged
- insulin resistance
- pulmonary embolism
- patient reported
- data analysis
- inferior vena cava
- skeletal muscle